Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19
NCT05595824
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
240
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
Molnupiravir (Esperavir)
DRUG:
Standard of care
Sponsor
Promomed, LLC